Smith & Nephew (LSE:SN.) has long been a frustrating stock for investors who admire the underlying medical-devices industry but want exposure to its growth and Margin profile. The company plays in some of the most attractive subsectors of the global devices market — orthopaedics, sports medicine and advanced wound management — yet has consistently traded at a discount to US peers such as Stryker, Zimmer Biomet and Medtronic. The reasons range from execution issues to portfolio mix to geographic exposure, and they have made the company a periodic target for activist investors. The arrival of Cevian Capital as a meaningful Shareholder, alongside ongoing delivery against chief executive Deepak Nath's 12-point operational plan, is the latest reason recent trading has put the shares squarely in focus.

A British company in a global devices market

Smith & Nephew's roots stretch back to a chemists' shop in Hull in 1856, but the modern group is a global medical-devices Business with three operating franchises: Orthopaedics, which makes hip and knee implants and trauma products; Sports Medicine and ENT, which supplies arthroscopic instruments, joint repair products and ear, nose and throat systems; and Advanced Wound Management, which provides wound care products for chronic and surgical wounds across hospitals and home settings.

Each of those franchises sits in a structurally attractive market. Orthopaedics benefits from ageing demographics and rising expectations of mobility into later life. Sports medicine is supported by both ageing populations and broader participation in active lifestyles. Advanced wound management is leveraged to chronic-disease prevalence, particularly diabetes, and to ongoing Investment in surgical care.

The challenge has not been market exposure but execution. Smith & Nephew has historically lagged peers on Margin and on growth, with operational issues including Supply-chain disruptions in robotics, inventory mis-management in some categories, and slower-than-peer commercial execution in priority markets. Successive management teams have set out to fix these issues, with results that have until recently been incremental rather than transformative.

Why the stock is in focus

Recent trading reflects a confluence of factors. Deepak Nath, in post since April 2022, has used his tenure to implement what the company describes as a 12-point plan — a structured operational programme covering Supply chain, commercial execution, Manufacturing, R&D efficiency and portfolio prioritisation. The plan has been credited with stabilising several pressure points, including hip and knee Supply, and with rebuilding commercial execution in priority US accounts.

More recently, the disclosure of Cevian Capital's stake brought activist scrutiny to the situation. Cevian, a Stockholm-based investor with a track record of pushing for strategic and operational improvements at large European companies, has not publicly demanded specific actions but its presence has raised questions about portfolio composition, Capital allocation and the pace of Margin recovery. Investors appear focused on whether the activist's involvement will accelerate the trajectory already in motion or shift the strategic dial in more material ways.

The move comes amid a broader rerating of the medical-devices sector, with US peers benefiting from strong elective procedure volumes, robust pricing and continued enthusiasm around robotics. Smith & Nephew's relative underperformance has narrowed in places, but the valuation gap remains — and the question of how much of that gap is structural versus cyclical is at the heart of the current debate.

The 12-point plan and what comes after it

The 12-point plan has been the company's core operational narrative since 2022. It addresses specific issues: Supply reliability for orthopaedic implants, particularly in the post-Pandemic environment; commercial execution in the US, where Smith & Nephew has historically been less effective in winning accounts than in defending them; productivity in R&D and the discipline around new product launches; and a more focused approach to Manufacturing and inventory. Management has provided regular progress updates against the plan, including specific cost and Margin targets.

Investors have responded to evidence of execution. Improvements in elective Volume capture, gradual recovery in operating margins and selected new product wins have helped narrow the perception gap with peers. The launch and scaling of the CORI surgical robotics platform has been a particular focus, with the system positioned as a more compact and price-accessible alternative to larger competitor robots.

What comes after the 12-point plan is now the strategic question. Management has signalled that the company will continue to invest in priority areas — robotics, hip and knee, sports medicine — while continuing to manage the wound management Business for cash generation and selective growth. Whether the structural Margin gap with US peers can be closed or merely narrowed will depend on the pace of execution against that next chapter.

China, VBP and emerging-market dynamics

China remains a particularly important variable. The country is one of the largest single markets for orthopaedic implants and surgical devices globally, and it has been reshaped by Volume-based procurement (VBP) — a centralised procurement system that drives down prices in exchange for Volume guarantees. VBP has compressed prices on hip and knee implants and on sports medicine consumables, with material consequences for Revenue per unit.

Smith & Nephew has navigated VBP alongside its peers, with management emphasising disciplined participation, careful pricing and the use of localised Manufacturing where appropriate. The medium-term effect of VBP has been to lower the Revenue contribution per unit while supporting Volume growth; the implications for sustainable Margin remain a live debate among investors.

Beyond China, the broader emerging-markets opportunity for medical devices remains substantial. Penetration of advanced surgical care, robotics-assisted surgery and modern wound management is meaningfully lower in many developing markets than in developed ones. Smith & Nephew has been investing in commercial infrastructure in selected geographies to capture that growth, balanced against the need to maintain Capital discipline.

Industry and FTSE context

Within the FTSE 100, Smith & Nephew is the only large-cap pure-play medical-devices company. That uniqueness has historically been both a help and a hindrance: a help in attracting UK and European mandates seeking healthcare exposure beyond pharmaceuticals, but a hindrance in that the natural comparable peers are listed on US exchanges, and global devices investors typically default to those names for sector exposure. The dual-listed nature of Smith & Nephew, with shares also trading on the New York Stock Exchange, partly bridges that gap.

The wider medical-devices sector benefits from secular tailwinds: ageing populations, rising healthcare expenditure, expanding insurance coverage in emerging markets and continued innovation in robotics, digital surgery and AI-driven imaging and analytics. Pricing dynamics have improved as procedure volumes have recovered post-Pandemic, and Capital flows into the sector have remained robust.

Competition has intensified in robotics. Stryker's Mako system has entrenched itself in many large US health systems, while Zimmer Biomet's Rosa platform continues to scale and Medtronic's Hugo system is being rolled out in selected markets. Smith & Nephew's CORI platform competes with all of those, and its commercial trajectory will be a meaningful driver of segment Economics in coming years.

Strategy, Balance Sheet and Capital allocation

Smith & Nephew has historically maintained a conservative Balance Sheet relative to many of its peers, with net Debt well within Investment-grade tolerances and free Cash Flow that, in normal years, comfortably covers dividends and selective bolt-on acquisitions. The Dividend has been a regular feature of the Equity story; its sustainability through cycles tends to be supported by the relatively stable Demand profile of medical-devices Revenue.

Capital allocation has skewed towards organic Investment — capacity, R&D and commercial infrastructure — rather than transformative M&A. Bolt-on acquisitions have been pursued selectively, particularly in sports medicine and adjacent areas. Activist scrutiny, where it appears, often raises the question of whether more aggressive portfolio actions, including potential divestitures, could surface value more quickly. The wound management Business has periodically been mentioned as a candidate for separation or strategic review, though the company has consistently emphasised its strategic value within the group.

Earnings quality has improved as Supply and execution issues have resolved, but the gap to US peers remains. Closing it will require a combination of Revenue growth above market in priority categories, continued Margin expansion and prudent reinvestment in innovation. None of those is impossible, but each requires sustained delivery.

Risks and counterarguments

The bear case rests on a long history of underperformance, the structural intensity of competition in orthopaedics and the difficulty of closing Margin gaps with US peers that benefit from greater scale and a different cost base. Sceptics argue that even with execution, Smith & Nephew may continue to trade at a discount because it lacks the breadth of Medtronic, the platform of Stryker or the dedicated focus of Zimmer Biomet on the same scale.

Operational risks include continued sensitivity to Supply-chain disruptions, the impact of further pricing pressure in China through additional VBP rounds, and the cost of competing on robotics in markets where peers have first-mover advantage. Currency moves can affect reported Earnings materially given the global Revenue mix, and the dual-listed structure means that translation effects flow through both UK and US disclosures.

Activist involvement is a double-edged sword. It can accelerate change and push management to articulate strategy more clearly, but it can also introduce short-term Volatility and force trade-offs between operational continuity and strategic restructuring. The path Cevian takes — quietly supportive, publicly engaged or actively interventionist — will shape one important dimension of the Equity story.

Counter-arguments point to the structural attractiveness of the company's end markets, the visible operational improvements already delivered, the optionality embedded in the robotics Franchise and the discount valuation versus peers as reasons to be constructive. Investors taking that view see the current set-up as one of the more interesting risk-reward configurations in European healthcare.

What investors will watch next

Several inputs will define the next leg of the Smith & Nephew story. Quarterly performance against the 12-point plan, particularly in margins, Supply reliability and US commercial execution, will continue to be a focus. Robotic system placements, both new and competitive conversions, will be parsed for evidence that CORI is gaining ground. Commentary on China VBP rounds and on broader emerging-market trends will affect how investors model the topline.

On the corporate side, any updates on Cevian's engagement and on the company's response, including potential portfolio actions or Capital-allocation changes, will be watched closely. Updates on R&D pipeline progress, particularly in sports medicine and advanced wound management, will provide additional context on Long-term Growth potential.

For now, Smith & Nephew remains one of the more interesting names on the FTSE 100 for investors looking for exposure to global medical devices through a UK listing. Recent trading has put the shares in focus precisely because the long-running gap between operational potential and Shareholder returns is finally being addressed in a more structured way. Whether the next phase narrows that gap meaningfully or merely incrementally is likely to determine the rerating opportunity from here.